Strategic Partnership Potential collaboration with contract manufacturers and analytical service providers (e.g., Leebio) for scalable production of fibrinogen and thrombin, offering St. Teresa access to cGMP capabilities and faster time-to-market.

Clinical Focus Target hospitals and surgical centers seeking advanced hemostasis solutions; emphasize SurgiClot CONTACT NANO-LIGATION technology as a differentiated hemostasis modality to reduce surgical bleeding and improve patient outcomes.

FinTech Growth Explore strategic funding and grant opportunities to support product development and regulatory milestones; identify potential investors aligned with medical devices and life sciences startups to scale commercialization.

Tech Enablement Leverage existing tech stack and digital marketing tools to raise awareness among surgeons and procurement teams; optimize online presence and analytics to drive inbound inquiries for partnerships and distributor channels.

Market Readiness Position as a niche, high-impact hemostasis solution with potential for alignment with large medical device distributors (e.g., McKesson, Cardinal Health, Henry Schein) to expand distribution and access to wider markets.